Risk Stratification of Patients With MF

Opinion
Video

Aaron Gerds, MD, MS, explains that unlike solid tumors, blood cancers are systemic, so risk stratification models like DIPSS that use readily available data on blood counts and physical exam are more useful prognostically; however, mutation analysis is becoming increasingly important for determining prognosis and targeting therapies.

Recent Videos
Surbhi Sidana, MD, an expert on multiple myeloma
Surbhi Sidana, MD, an expert on multiple myeloma
Surbhi Sidana, MD, an expert on multiple myeloma
Surbhi Sidana, MD, an expert on multiple myeloma
Surbhi Sidana, MD, an expert on multiple myeloma
Surbhi Sidana, MD, an expert on multiple myeloma
Surbhi Sidana, MD, an expert on multiple myeloma
1 KOL is featured in this series.
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Related Content